Global Cancer Minimal Residual Disease Testing Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Cancer Minimal Residual Disease Testing market size was valued at US$ 1135 million in 2024 and is forecast to a readjusted size of USD 1794 million by 2031 with a CAGR of 6.8% during review period.
Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
The market for cancer MRD testing is likely to grow as precision medicine and personalized treatment approaches become more prominent in cancer care. MRD testing can play a significant role in tailoring treatment plans to individual patients.
This report is a detailed and comprehensive analysis for global Cancer Minimal Residual Disease Testing market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cancer Minimal Residual Disease Testing market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cancer Minimal Residual Disease Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cancer Minimal Residual Disease Testing market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health, ICON plc, Invivoscribe, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Cancer Minimal Residual Disease Testing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Market segment by Application
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Major players covered
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cancer Minimal Residual Disease Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cancer Minimal Residual Disease Testing, with price, sales quantity, revenue, and global market share of Cancer Minimal Residual Disease Testing from 2020 to 2025.
Chapter 3, the Cancer Minimal Residual Disease Testing competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Minimal Residual Disease Testing breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Cancer Minimal Residual Disease Testing market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cancer Minimal Residual Disease Testing.
Chapter 14 and 15, to describe Cancer Minimal Residual Disease Testing sales channel, distributors, customers, research findings and conclusion.
Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
The market for cancer MRD testing is likely to grow as precision medicine and personalized treatment approaches become more prominent in cancer care. MRD testing can play a significant role in tailoring treatment plans to individual patients.
This report is a detailed and comprehensive analysis for global Cancer Minimal Residual Disease Testing market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cancer Minimal Residual Disease Testing market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cancer Minimal Residual Disease Testing market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cancer Minimal Residual Disease Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cancer Minimal Residual Disease Testing market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health, ICON plc, Invivoscribe, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Cancer Minimal Residual Disease Testing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Market segment by Application
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Major players covered
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cancer Minimal Residual Disease Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cancer Minimal Residual Disease Testing, with price, sales quantity, revenue, and global market share of Cancer Minimal Residual Disease Testing from 2020 to 2025.
Chapter 3, the Cancer Minimal Residual Disease Testing competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Minimal Residual Disease Testing breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Cancer Minimal Residual Disease Testing market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cancer Minimal Residual Disease Testing.
Chapter 14 and 15, to describe Cancer Minimal Residual Disease Testing sales channel, distributors, customers, research findings and conclusion.
Table of Contents
140 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Cancer Minimal Residual Disease Testing by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
